These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 4038404)

  • 1. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
    Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
    J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
    Sinkule JA; Evans WE
    J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
    Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
    J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
    Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H
    Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
    van Prooijen HC; Muus P; Roelofs JM; Punt K
    Scand J Haematol; 1986 Jan; 36(1):123-6. PubMed ID: 3456631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.
    Wermeling JR; Pruemer JM; Hassan FM; Warner A; Pesce AJ
    Clin Chem; 1989 Jun; 35(6):1011-5. PubMed ID: 2731341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.
    Yang JL; White JC; Capizzi RL
    Cancer Chemother Pharmacol; 1990; 26(2):135-8. PubMed ID: 2347039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum.
    Houzé P; Deschamps F; Dombret H; Bousquet B; Gourmel B
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):185-92. PubMed ID: 11318414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of cytosine arabinoside and its metabolite, uracil arabinoside, in human plasma using hydrophilic interaction liquid chromatography with UV detection.
    Uchiyama M; Takamatsu Y; Ogata K; Matsumoto T; Jimi S; Tamura K; Hara S
    Biomed Chromatogr; 2013 Jul; 27(7):818-20. PubMed ID: 23420764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-performance liquid chromatographic assay for cytosine arabinoside and uracil arabinoside in cerebrospinal fluid and plasma.
    Riccardi A; Servidei T; Lasorella A; Riccardi R
    J Chromatogr; 1989 Dec; 497():302-7. PubMed ID: 2625467
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation.
    Capizzi RL; Yang JL; Rathmell JP; White JC; Cheng E; Cheng YC; Kute T
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):65-74. PubMed ID: 3892704
    [No Abstract]   [Full Text] [Related]  

  • 17. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W; Woodcock TM; Gordon CS; Krakoff IH
    Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
    Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety.
    Turcotte JG; Srivastava SP; Steim JM; Calabresi P; Tibbetts LM; Chu MY
    Biochim Biophys Acta; 1980 Sep; 619(3):619-31. PubMed ID: 7459369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
    Radeski D; Cull GM; Cain M; Hackett LP; Ilett KF
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):765-8. PubMed ID: 20532508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.